Classical Hodgkin Lymphoma Clinical Trial
Official title:
Social Inequalities in the Participation and Activity in Children and Adolescents With Hodgkin-lymphoma. A Prospective Multicenter Cohort Study of Social and Personal Influencing Factors
Purpose of this study is to determine the influence of social factors on participation and activity among children and adolescents aged 10-18 years with hodgkin-lymphoma. Furthermore personal and treatment-related factors and their impact on participation will be explored.
Status | Not yet recruiting |
Enrollment | 700 |
Est. completion date | February 2020 |
Est. primary completion date | February 2020 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 10 Years to 18 Years |
Eligibility |
Inclusion Criteria: - histologically confirmed primary diagnosis of classical Hodgkin's Lymphoma - 10-18 years - written informed consent of the patient and/or the patient's parents or guardian according to national laws Exclusion Criteria: - other (simultaneous) malignancies |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Martin-Luther-Universität Halle-Wittenberg | German Cancer Aid, University of Giessen |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Parental coping with chronic childhood disease | Coping Health Inventory for Parents, CHIP (parental questionnaire) | one month after diagnosis until two years | No |
Other | Consequences of chronic conditions and disability in childhood and adolescence for the family | Impact on Family Scale in Families with Children with Disabilities, FaBel (parental questionnaire) | one month after diagnosis until two years | No |
Other | Family atmosphere | Family Environment Scale, FES (parental questionnaire) | one month after diagnosis until two years | No |
Other | Psychosocial needs | Short-Form Supportive Care Needs Survey Questionnaire, SCNS-SF34 (parental questionnaire) | one month after diagnosis until two years | No |
Other | Use of psychosocial care services | (parental questionnaire) | one month after diagnosis until two years | No |
Other | Satisfaction with treatment | Questionnaire to assess the Satisfaction with the Treatment, FBB (parental questionnaire) | one month after diagnosis until two years | No |
Primary | Social participation | The Child and Adolescent Scale of Participation, CASP | one month after diagnosis until two years | No |
Primary | Quality of life | Questionnaire to assess Health Related Quality of Life in chronically ill Children and Adolescents, KINDL | one month after diagnosis until two years | No |
Secondary | Understanding of illness | Illness Perception Questionnaire, IPQ | one month after diagnosis until two years | No |
Secondary | Autonomy | Subscale Autonomy from the Health-Related Quality of Life Questionnaire for Children and Adolescents, Kidscreen | one month after diagnosis until two years | No |
Secondary | Self-efficacy | Self-Efficacy for Managing Chronic Disease 6-Item Scale, SES6 | one month after diagnosis until two years | No |
Secondary | Optimism | Subscale from The Bern Subjective Well-Being Questionnaire for Adolescents, BFW | one month after diagnosis until two years | No |
Secondary | Coping | Coping Questionnaire for Children and Adolescents, CODI | one month after diagnosis until two years | No |
Secondary | Sense of coherence | Children Sense of Coherence Scale, C-SOC | one month after diagnosis until two years | No |
Secondary | Behavioural disorders and strengths | Strengths and Difficulties Questionnaire, SDQ | one month after diagnosis until two years | No |
Secondary | Fatigue | Subscale Fatigue from the Questionnaire to assess Quality of Life of Cancer Patients developed by the European Organisation for Research and Treatment of Cancer, EORTC QLQ-C30 | one month after diagnosis until two years | No |
Secondary | Satisfaction with treatment | Questionnaire to assess the Satisfaction with the Treatment, FBB | one month after diagnosis until two years | No |
Secondary | Social support | Social Support Scale, SSS | one month after diagnosis until two years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06018129 -
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03212404 -
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT04288726 -
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
|
Phase 1 | |
Recruiting |
NCT04486391 -
Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
|
Phase 3 | |
Active, not recruiting |
NCT05008224 -
Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
|
Phase 2 | |
Active, not recruiting |
NCT02684708 -
Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
|
Phase 3 | |
Active, not recruiting |
NCT03226249 -
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT03739619 -
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT03327571 -
B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes
|
||
Recruiting |
NCT03652441 -
Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
|
Phase 2 | |
Completed |
NCT02243436 -
Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Terminated |
NCT04254107 -
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05714553 -
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
Completed |
NCT02981914 -
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
|
Early Phase 1 | |
Withdrawn |
NCT04952584 -
Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas
|
Phase 1 | |
Withdrawn |
NCT03205891 -
Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas
|
Phase 1 | |
Recruiting |
NCT02332668 -
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
|
Phase 1/Phase 2 | |
Completed |
NCT04858568 -
Immune Responses to COVID-19 Vaccination in Lymphoma Patients
|
||
Active, not recruiting |
NCT02824029 -
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
|
Phase 2 | |
Recruiting |
NCT05900765 -
A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma
|
Phase 2 |